South San Francisco, California, USA

Structure Therapeutics

Clinical-stage biotechnology company developing oral small-molecule (non-peptide) medicines that act on GPCR receptors. Its lead candidate, aleniglipron (GSBR-1290), is an investigational oral GLP-1 receptor agonist for obesity and is not approved anywhere. The company reports no product revenue.

Aleniglipron in Phase 3 (investigational)

In its September 2026 announcement Structure said two Phase 3 trials of aleniglipron, ACCOMPLISH-1 and ACCOMPLISH-2, are enrolling, with topline data expected in the second half of 2028.[src]

No products approved, no revenue

Structure's 10-K states it has no products approved for commercial sale and has not generated any revenue to date. It reported a net loss of US$141.2 million for 2025 and cash, cash equivalents and short-term investments of US$1,446.2 million at December 31, 2025.[src]

Oral GLP-1 patent licence to Genentech and Roche

The 10-K states that in December 2025 Structure's subsidiary Gasherbrum granted Genentech, Inc. and F. Hoffmann-La Roche Ltd a non-exclusive, sublicensable, royalty-bearing licence under certain patents covering a class of oral GLP-1 receptor agonists that is different from aleniglipron.[src]